Value Microcaps Zip Code Changers

[zenvesting]

COV.v & MBX.to: I don't trust myself to evaluate new technology and pick winners and losers either; but the beauty of both COV.v and MBX.to is that both of these stocks already have very compelling third party validation of their technologies, validation that would command much higher premiums if these stocks were traded in U.S. markets IMO:

1.) For Covalon, they signed a licensing and distribution agreement with the market leader in their segment....and their partner, as a private company, issued a news release about the agreement whic seams to suggest this will be a major product addition to their portfolio:
http://www.molnlycke.com/news-media/press-releases/Expanding-antimicrobial-wound-care-dressing-product-offering/

“Adding an antimicrobial film dressing to our product portfolio is the next step in reinforcing our position as a global leader in advanced wound care and part of our commitment to help clinicians in the fight against hospital acquired infections.”


2.a.) For Microbix, their Virusmax patents and technology just got some significant validation from the European Patent office upholding their patent and all it's claims against a challenge from Novatis:
http://microbix.com/category/newsroom/

(This alone would command a much higher market cap if it was just some patent troll company trading on NASDAQ IMO....and I like this company more because they aren't patent trolls, they developed the technology while working in their virology business.)

2.b.) ...their Lumisort technology has been validated with a proof of concept, a third party investor making a big investment in it, and the market potential has been validated by LOI's with 25% of the global livestock genetics companies.

2.c.) ...their Urokinase technology is validated through a long history of safe use as an FDA approved product, having reached sales of $274M in 1998, before the FDA cited Abbott Laboratories with cGMP violations for it's production facilites, then Abbot Laboratories sold-off their hospital products division. Microbix now needs to find a new partner to produce and market the product and based on them saying the will update on this in Q2 2014, I have a hunch one or more might be in negotiations now.